Howard Rutman, MD, MBA

Xalud Therapeutics
New York, NY, United States

Dr. Howard Rutman is the Chief Medical Officer of Xalud Therapeutics where he oversees the development of plasmid-DNA based therapies for inflammation and neurodegenerative diseases. Since joining Xalud in April 2021, Howard has been responsible for the clinical development program for XT-150, an IL-10 based transgene therapy, currently in clinical trials for osteoarthritis and in preclinical evaluation for ALS.

Presentation(s):

• 0314: Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial

  Sunday, November 12, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.

• 0818: Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Results of a Phase 2 Trial

  Sunday, November 12, 2023
  4:15 PM – 4:25 PM PT

  Disclosure information not submitted.